INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Dec 17, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 230,350 | $179.13 | 1,066,484 |
Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 196,430 | $28.01 | 1,066,135 |
Dec 16, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 42,974 | $272.73 | 1,063,638 |
Jun 23, 2021 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Other acquisition or disposition | -- | -- | 987,483 |
Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 94,551 | $58.19 | 971,584 |
Feb 15, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 129,902 | $8.50 | 962,943 |
Feb 15, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,103 | $109.29 | 952,840 |
Aug 05, 2021 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 50,000 | $600.06 | 937,483 |
Aug 13, 2021 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 773 | $625.00 | 936,710 |
Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 3,570 | $28.01 | 928,701 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.